Little Debbie (McKee Foods) has rolled out a Chocolate Old Fashioned Donut nationwide in the United States, expanding on the strong consumer response to its original Old Fashioned Donut first introduced in June 2025. The chocolate version is described as a cake-style donut with a chocolatey flavor, crumbly texture and sugary glaze. It is available in three formats: a retro-inspired Big Pack Carton containing six large donuts and two single-serve 3-ounce individually wrapped options for on-the-go convenience. The company says the new flavor will join the original as a permanent addition to the Little Debbie snack lineup and is shipping to major retailers, grocery chains and convenience stores. The launch coincides with other Little Debbie product introductions, including soft-baked Chocolate Chip and Peanut Butter cookies. Brand manager Scott Brownlow emphasized the decision to “double down” on the Old Fashioned Donut franchise after what the company called massive consumer demand and strong retail performance for the 2025 launch.

Kailera Therapeutics raised $625 million in an initial public offering and began trading on Nasdaq on April 17, 2026 under the ticker KLRA. The biotech sold roughly 39.06 million shares at $16 each and the stock opened at $26, a surge of about 62.5% from the offering price. The deal, one of the largest biotech IPOs in recent years, pushed the company’s valuation into the low billions after the first-day pop. Kailera is developing multiple GLP-1–class obesity treatments, including a global Phase 3 injectible GLP-1/GIP candidate and an oral GLP-1 program; key late-stage readouts for the lead program are not expected until 2028. Backers include prominent venture investors such as Bain Capital, Atlas Venture and Arch Venture Partners. The listing underscores strong investor appetite for obesity drugs as established players like Novo Nordisk and Eli Lilly dominate a market projected to reach roughly $150 billion annually by the end of the decade.

Spirit Airlines has asked the U.S. administration for hundreds of millions of dollars in emergency aid as a sharp rise in jet fuel prices threatens its planned exit from bankruptcy, Reuters and other outlets reported on April 16-17, 2026. The carrier is due to meet Transportation Secretary Sean Duffy next week after the Department of Transportation requested a review of the financial health of smaller U.S. carriers. Spirit, which filed for Chapter 11 twice (most recently in August 2025), is pursuing a deep restructuring that would shrink its fleet to about 76-80 aircraft by mid-2026. The company built its turnaround on fuel assumptions near $2.20 a gallon; mid-April jet fuel traded around $4.20–$4.88 a gallon after the war in Iran, prompting JP Morgan to estimate an incremental $360 million hit and a potential 2026 operating margin near negative 20%. Creditors including Citibank have objected to Spirit’s reorganisation projections and warned that defaults could lead to collateral repossession and possible liquidation, though sources say immediate shutdown is not the most likely outcome. Spirit says it continues to operate normally.

Alamar Biosciences fetched a $1.53 billion valuation after its Nasdaq debut on April 17, 2026, when shares opened at $22.60 versus an offer price of $17, a roughly 33% first-day gain. The Fremont, California-based proteomics company sold about 11.3 million shares in an upsized offering at the top of its marketed range, raising roughly $191.3 million. Founded in 2018, Alamar develops the NULISA-based precision proteomics platform to detect low-level protein biomarkers for neurology, immunology and other disease areas; revenue grew to just over $74 million in 2025, roughly triple year-on-year. Market commentary linked the successful listing to a revived IPO market as geopolitical tensions eased. Independent market reports also noted institutional interest following the listing, including a reported purchase of 537,500 shares by ARK Investment Management. Some post-IPO coverage flagged limited historical financial metrics — no meaningful P/E and proprietary scorecards that lack data — underscoring early-stage risks despite strong investor demand.

India’s Directorate General of Foreign Trade on April 17 issued a delayed order naming 15 banks authorised by the Reserve Bank of India to import gold and silver from April 1, 2026 to March 31, 2029, ending a hold-up that forced banks to halt new bullion purchases. The list, which did not explain the delay, allows major lenders including State Bank of India, HDFC Bank and Bank of India to import both metals; Union Bank of India and Sberbank are permitted to import only gold. Traders had reported more than 5 metric tonnes of gold and about 8 tonnes of silver stuck at customs while awaiting clearance, and banks had paused fresh overseas orders. The disruption coincided with preparations for the Akshaya Tritiya festival and came amid wider government efforts to manage the trade deficit as oil and other import costs rise. Market sources said inventories had drawn down and jewellery demand, ETF flows and premiums could be affected until customs clearances resume.

Apple’s iPhone shipments in China jumped about 20% year-on-year in Q1 2026, the strongest growth among major vendors, Counterpoint Research data showed on April 17. That outpaced an overall 4% decline in China smartphone shipments and helped Apple reclaim a 19% market share behind Huawei’s 20%. Counterpoint and other analysts said strong demand for the iPhone 17 series, targeted promotions and government subsidies, plus Apple’s premium mix and tight supply-chain control, let it absorb rising memory-chip costs better than many rivals. Xiaomi plunged roughly 35% on a high-comparison base and weaker new models, while Oppo, Honor and Vivo saw small declines or modest gains. Markets responded: Apple shares rose around 2–3% on April 17 as brokers including BNP Paribas and Societe Generale upgraded the stock and Bank of America highlighted Apple’s on-device AI strategy and upcoming M5 chips. Market-watchers note Apple’s high GF/market scores but flag valuation premiums and roughly $24.2m of insider selling in recent months. Broader market rallies that day were also aided by easing Middle East shipping fears, which weighed on oil and lifted risk appetite.